| |
HR
|
95% CI
|
p value
|
|---|
|
Older age
|
0.78
|
0.35–1.65
|
0.52
|
|
Sex (male)
|
1.95
|
0.75–6.64
|
0.18
|
|
Etiology of ESRD
|
|
DN
|
1.30
|
0.61–2.74
|
0.50
|
|
NS
|
0.58
|
0.17–1.50
|
0.28
|
|
CGN
|
0.96
|
0.32–2.34
|
0.94
|
|
ADPKD
|
–
|
–
|
–
|
|
IgAN
|
0.81
|
0.20–4.15
|
0.78
|
|
Other or unknown
|
1.13
|
0.27–3.23
|
0.85
|
|
Smoking history
|
0.83
|
0.38–1.92
|
0.64
|
|
DM
|
1.95
|
0.87–4.95
|
0.11
|
|
Dyslipidemia
|
1.46
|
0.69–3.31
|
0.33
|
|
CVD
|
0.75
|
0.35–1.58
|
0.45
|
|
IHD
|
0.74
|
0.22–1.93
|
0.57
|
|
CHF
|
1.25
|
0.20–4.20
|
0.77
|
|
Stroke
|
0.27
|
0.02–1.29
|
0.12
|
|
PAD
|
0.56
|
0.13–1.60
|
0.31
|
|
RASI
|
1.69
|
0.80–3.71
|
0.17
|
|
Statin
|
1.41
|
0.67–3.10
|
0.37
|
|
Warfarin
|
0.61
|
0.10–2.03
|
0.46
|
|
Antiplatelet agents
|
0.45
|
0.21–0.95
|
0.036
|
|
AVF anastomosis type (%)
|
|
Radiocephalic
|
3.22
|
0.96–20.0
|
0.060
|
|
Brachiocephalic
|
0.36
|
0.06–1.21
|
0.11
|
- We defined individuals aged > 71 years as “the older age”
- VA vascular access, VAIVT vascular access intervention therapy, HR hazard ratio, CI confidence interval, ESRD end-stage renal disease, DN diabetic nephropathy, NS nephrosclerosis, CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease, IgAN IgA nephropathy, DM diabetes mellitus, CVD cardiovascular disease, IHD ischemic heart disease, CHF congestive heart failure, PAD peripheral artery disease, RASI renin–angiotensin–aldosterone system inhibitor, AVF arteriovenous fistula
